Compare Dr. Reddys with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 22.3 24.3 91.9% View Chart
P/BV x 3.3 2.5 134.6% View Chart
Dividend Yield % 0.7 0.6 109.2%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
CIPLA
Mar-19
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,875678 424.0%   
Low Rs1,888484 390.2%   
Sales per share (Unadj.) Rs930.2198.2 469.3%  
Earnings per share (Unadj.) Rs117.418.5 633.9%  
Cash flow per share (Unadj.) Rs185.835.0 530.9%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %0.80.5 162.6%  
Book value per share (Unadj.) Rs844.4186.3 453.2%  
Shares outstanding (eoy) m166.07805.70 20.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.9 87.4%   
Avg P/E ratio x20.331.4 64.7%  
P/CF ratio (eoy) x12.816.6 77.2%  
Price / Book Value ratio x2.83.1 90.5%  
Dividend payout %17.016.2 105.2%   
Avg Mkt Cap Rs m395,496468,031 84.5%   
No. of employees `00022.022.6 97.0%   
Total wages/salary Rs m33,56228,565 117.5%   
Avg. sales/employee Rs Th7,032.87,053.1 99.7%   
Avg. wages/employee Rs Th1,527.91,261.5 121.1%   
Avg. net profit/employee Rs Th887.7659.1 134.7%   
INCOME DATA
Net Sales Rs m154,482159,710 96.7%  
Other income Rs m3,3754,766 70.8%   
Total revenues Rs m157,857164,475 96.0%   
Gross profit Rs m31,78230,973 102.6%  
Depreciation Rs m11,34813,263 85.6%   
Interest Rs m8891,684 52.8%   
Profit before tax Rs m22,92020,791 110.2%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8585,695 67.7%   
Profit after tax Rs m19,50014,924 130.7%  
Gross profit margin %20.619.4 106.1%  
Effective tax rate %16.827.4 61.4%   
Net profit margin %12.69.3 135.1%  
BALANCE SHEET DATA
Current assets Rs m111,101124,266 89.4%   
Current liabilities Rs m58,97337,715 156.4%   
Net working cap to sales %33.754.2 62.3%  
Current ratio x1.93.3 57.2%  
Inventory Days Days7991 87.6%  
Debtors Days Days9495 99.3%  
Net fixed assets Rs m101,245105,190 96.2%   
Share capital Rs m8301,611 51.5%   
"Free" reserves Rs m139,406148,511 93.9%   
Net worth Rs m140,236150,123 93.4%   
Long term debt Rs m22,00038,301 57.4%   
Total assets Rs m224,656239,633 93.7%  
Interest coverage x26.813.3 200.7%   
Debt to equity ratio x0.20.3 61.5%  
Sales to assets ratio x0.70.7 103.2%   
Return on assets %9.16.9 130.9%  
Return on equity %13.99.9 139.9%  
Return on capital %14.911.8 126.3%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67357,410 154.5%   
Fx outflow Rs m19,10419,041 100.3%   
Net fx Rs m69,56938,368 181.3%   
CASH FLOW
From Operations Rs m28,70416,911 169.7%  
From Investments Rs m-7,727-16,687 46.3%  
From Financial Activity Rs m-21,326-3,487 611.6%  
Net Cashflow Rs m-314-3,451 9.1%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 20, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS